Company Overview
Snapshot
Founded in January 2024 by Dan Davidi, OHR Synbiosis operates with 11–50 employees. The company has secured funding across one round from 4 investors, including Aleph and Deep33, in January 2026.
Business overview
OHR Synbiosis is a synthetic biology company focused on sustainable chemical manufacturing. The company develops a novel platform that utilizes engineered enzymes to transform CO₂-derived feedstocks into precise carbon chains, thereby eliminating the need for traditional petroleum-based refining processes. This technology enables the production of bio-based materials, such as sulfur-free fuels, supporting decarbonization and circular economy objectives. OHR Synbiosis offers a scalable and cost-effective alternative to conventional petrochemical manufacturing, with applications across various industrial sectors.
Log in to access full profile ›Company Intelligence Q&A
- When was OHR Synbiosis founded?
- OHR Synbiosis was founded in January 2024.
- Who are the founders of OHR Synbiosis?
- Dan Davidi is the Founder & CEO of OHR Synbiosis.
- What is OHR Synbiosis's primary focus?
- OHR Synbiosis focuses on sustainable chemical manufacturing through synthetic biology, leveraging engineered enzymes to convert CO₂-derived feedstocks into bio-based materials.
- Which investors participated in OHR Synbiosis's funding round?
- In January 2026, OHR Synbiosis received funding from investors including Aleph and Deep33.
- What kind of products does OHR Synbiosis's technology enable?
- OHR Synbiosis's technology enables the production of bio-based materials, such as sulfur-free fuels, offering an alternative to traditional petroleum-based products.